MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with P

Pemigatinib

Pemigatinib 4.5mg tablets

No stability information

Stability notes for Pemigatinib 4.5mg tablets

There are no stability notes for this medicine.

Supplier

Pemazyre 4.5mg tablets (Incyte Biosciences UK Ltd)

Pemigatinib 9mg tablets

No stability information

Stability notes for Pemigatinib 9mg tablets

There are no stability notes for this medicine.

Supplier

Pemazyre 9mg tablets (Incyte Biosciences UK Ltd)

Pemigatinib 13.5mg tablets

No stability information

Stability notes for Pemigatinib 13.5mg tablets

There are no stability notes for this medicine.

Supplier

Pemazyre 13.5mg tablets (Incyte Biosciences UK Ltd)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.